Your browser doesn't support javascript.
loading
Image-Guided Stereotactic Body Radiotherapy on Detectable Prostate Bed Recurrence after Prostatectomy in RT-Naïve Patients.
Santamaria, Riccardo; Zaffaroni, Mattia; Vincini, Maria Giulia; Colombi, Lorenzo; Gaeta, Aurora; Mastroleo, Federico; Corrao, Giulia; Zerini, Dario; Villa, Riccardo; Mazzola, Giovanni Carlo; Alessi, Sarah; Luzzago, Stefano; Mistretta, Francesco Alessandro; Musi, Gennaro; De Cobelli, Ottavio; Gandini, Sara; Kuncman, Lukasz; Cattani, Federica; Ceci, Francesco; Petralia, Giuseppe; Marvaso, Giulia; Jereczek-Fossa, Barbara Alicja.
Afiliação
  • Santamaria R; Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, 20139 Milan, Italy.
  • Zaffaroni M; Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, 20139 Milan, Italy.
  • Vincini MG; Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, 20139 Milan, Italy.
  • Colombi L; Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, 20139 Milan, Italy.
  • Gaeta A; Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy.
  • Mastroleo F; Department of Experimental Oncology, European Institute of Oncology IRCCS, 20139 Milan, Italy.
  • Corrao G; Department of Statistics and Quantitative Methods, University of Milan-Bicocca, 20126 Milan, Italy.
  • Zerini D; Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, 20139 Milan, Italy.
  • Villa R; Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy.
  • Mazzola GC; Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, 20139 Milan, Italy.
  • Alessi S; Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy.
  • Luzzago S; Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, 20139 Milan, Italy.
  • Mistretta FA; Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, 20139 Milan, Italy.
  • Musi G; Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy.
  • De Cobelli O; Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, 20139 Milan, Italy.
  • Gandini S; Division of Radiology, European Institute of Oncology IRCCS, 20139 Milan, Italy.
  • Kuncman L; Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy.
  • Cattani F; Division of Urology, European Institute of Oncology IRCCS, 20139 Milan, Italy.
  • Ceci F; Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy.
  • Petralia G; Division of Urology, European Institute of Oncology IRCCS, 20139 Milan, Italy.
  • Marvaso G; Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy.
  • Jereczek-Fossa BA; Division of Urology, European Institute of Oncology IRCCS, 20139 Milan, Italy.
Life (Basel) ; 14(7)2024 Jul 11.
Article em En | MEDLINE | ID: mdl-39063623
ABSTRACT
Purpose or Objective-The aim of the study is to evaluate the efficacy and safety of SBRT on detectable prostate bed recurrence in RT-naïve prostate cancer patients. MATERIALS AND

METHODS:

Eighty-six patients who underwent SBRT for macroscopic bed recurrence after prostatectomy were retrospectively included. Patients were treated based on mpMRI or choline/PSMA PET.

RESULTS:

The median time to biochemical relapse (BCR) after RP was 46 months, with a median PSA at restaging of 1.04 ng/mL. Forty-six patients were staged with mpMRI and choline/PSMA PET, while ten and thirty were treated based on PET and MRI only, respectively. Only one late G ≥ 2 GI toxicity was observed. With a median BCR follow-up of 14 months, twenty-nine patients experienced a BCR with a median PSA at recurrence of 1.66 ng/mL and a median survival free from the event of 40.1 months. The median time to BCR was 17.9 months. Twenty-seven patients had clinical relapse (CR), with a median CR follow-up of 16.27 months and a median time to CR of 23.0 months. Biochemical recurrence-free survival at one and two years was 88% and 66%, respectively, while clinical recurrence-free survival at one and two years was 92% and 82%, respectively. Regarding local relapses, seven were in the field of treatment, while eight of them were outside the field of treatment.

CONCLUSIONS:

Data showed that SBRT targeting only the macroscopic bed recurrence instead of the whole prostate bed is safe and effective. Additional data and longer follow-ups will provide a clearer indication of the appropriate treatment and staging methodology for these patients.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article